Breast carcinoma remains the most common malignancy of women around the world, and despite the advances in the early diagnosis and adjuvant treatment of this disease, many women still relapse with ...

Evans was one of the investigators on REFLECT, which showed Lenvima had an overall survival benefit that is comparable to that seen with Nexavar in first line therapy.

Bayer’s liver cancer treatment Nexavar has been judged not to be value for money by England’s cost effectiveness watchdog NICE. The drug is currently available for this indication via the ...